Quintrio
Home

MEASURING & CONTROLLING DEVICES, NEC

Quantum-Si Incorporated Class A Common Stock

QSI

Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.

Last trade $1.01
Day change -$0.055 (-5.19%)
Day range $0.993 – $1.08
Volume 3,967,680
Market cap $233M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$232.93M
Price / earnings
—
Price / book
1.45×
Price / sales
184.13×
EV / sales
163.91×
EV / EBITDA
-2.31×

Profitability

Earnings per share
-$0.39
Return on assets
-49.24%
Return on equity
-53.13%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.64×
Quick ratio
9.5×
Cash ratio
2.19×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$81.35M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for QSI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$212K$344K$258K$451K$552K$591K$842K$1.19M
Cost of revenue$138K$172K$184K$329K$358K$240K$356K$582K
Gross profit$74K$172K$74K$122K$194K$351K$486K$610K
Selling, general and administrative$10.07M$9.98M$9.64M$10.27M$10.71M$11.9M$11.88M$14.3M
Research and development$13.78M$15.82M$14.49M$10.95M$13.88M$15.21M$13.72M$16.99M
Total operating expenses$23.85M$25.8M$24.13M$21.22M$26.39M$30.47M$25.6M$31.29M
Operating income-$23.78M-$25.63M-$24.05M-$21.09M-$26.2M-$30.12M-$25.11M-$30.68M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$22.32M-$23.53M-$21.79M-$17.6M-$35.68M-$28.82M-$19.18M-$33.11M
Income taxes$0$0-$122K$8K$19K$20K$11K$13K
Net income-$22.32M-$23.53M-$21.67M-$17.61M-$35.7M-$28.84M-$19.19M-$33.12M
Net income attributable to common shareholders-$22.32M-$23.53M-$21.67M-$17.61M-$35.7M-$28.84M-$19.19M-$33.12M
EBITDA-$22.61M-$24.4M-$22.83M-$19.92M-$25.02M-$28.93M-$24.2M-$29.68M
Basic earnings per share-$0.10-$0.11-$0.10-$0.08-$0.17-$0.16-$0.11-$0.23
Diluted earnings per share-$0.10-$0.11-$0.10-$0.08-$0.17-$0.16-$0.11-$0.23

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Quantum-Si Incorporated announced the grant of 495,335 restricted stock units to new employees under its 2023 Inducement Equity Incentive Plan. The RSUs will vest 25% on December 20, 2027, with the remainder vesting quarterly thereafter, subject to continued employment. The company's Proteus platform remains on track for anticipated Q2 2027 commercial launch.

Zacks Investment Research

Quantum-Si Incorporated (QSI) Reports Q3 Loss, Misses Revenue Estimates

Quantum-Si Incorporated reported a Q3 loss of $0.10 per share, beating expectations of $0.13 loss, but significantly missed revenue estimates with $0.21 million versus consensus. Revenues declined 62% year-over-year from $0.55 million. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Despite outperforming the S&P 500 by 5% year-to-date, the stock faces headwinds from weak revenue performance.

GlobeNewswire Inc.

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

Quantum-Si announced interim development results for its next-generation Proteus platform, showing significant performance improvements over its commercially available Platinum Pro instrument. In control peptide studies, Proteus delivered 30 times more alignments per single chamber, achieved a 4.8-fold lower false discovery rate, and identified 1.6-2.0 times more peptides in protein mixtures. The company projects a full four-chamber Proteus run could deliver approximately 60 times more alignments than a two-chamber Platinum Pro run. Proteus is expected to launch in Q2 2027.

The Motley Fool

Why Quantum-Si Stock Flopped on Friday

Quantum-Si filed a shelf registration with the SEC to potentially raise up to $300 million through various securities, causing investor concern about potential stock dilution and leading to a nearly 5% stock price decline.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.